In vitro pharmacokinetics of sirolimus-coated stent for tracheal stenosis
Purpose: To investigate the in vitro pharmacokinetics of sirolimus-coated stent for tracheal stenosis
Methods: Naked nickel titanium alloy stent was placed in methylene chloride leaching solution with different ratios of sirolimus/poly(lactic-co-glycolic acid) (PLGA). The morphology, thickness, and pellicles on the surface of the stent were observed by scanning electronic microscopy. Drug release from the stent was determined by enzyme amplification immunoassay.
Results: Sirolimus was smoothly and uniformly attached to the stent, with an optimal sirolimus: PLGA coating ratio of 1:10. Further increases in sirolimus: PLGA ratio did not improve stent drug loading. A slow release of sirolimus from the stent was observed in the first week, followed by a rapid release and then much slower release process. Release of sirolimus persisted in the stent throughout the period of 42 days.
Conclusion: The sirolimus-coated stent has a good surface morphology, and sustained and effective drug release characteristics. Thus, it may be effective and safe for use in the treatment of tracheal stenosis in vivo.
Keywords: Tracheal stenosis, Sirolimus, Drug-coated stents, poly(lactic-co glycolic acid) PLGA
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.